1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Avidity Partners Management LP Buys Seattle Genetics Inc, Merck Inc, McKesson Corp, Sells Baxter International Inc, HCA Healthcare Inc, Zimmer Biomet Holdings Inc

Investment company Avidity Partners Management LP (Current Portfolio) buys Seattle Genetics Inc, Merck Inc, McKesson Corp, AbbVie Inc, Biomarin Pharmaceutical Inc, sells Baxter International Inc, HCA Healthcare Inc, Zimmer Biomet Holdings Inc, Edwards Lifesciences Corp, Axonics Modulation Technologies Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Avidity Partners Management LP. As of 2020Q1, Avidity Partners Management LP owns 52 stocks with a total value of $724 million. These are the details of the buys and sells.

For the details of Avidity Partners Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/avidity+partners+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Avidity Partners Management LP
  1. Seattle Genetics Inc (SGEN) - 580,000 shares, 9.25% of the total portfolio. New Position
  2. Merck & Co Inc (MRK) - 492,000 shares, 5.23% of the total portfolio. New Position
  3. AbbVie Inc (ABBV) - 477,000 shares, 5.02% of the total portfolio. Shares added by 407.45%
  4. McKesson Corp (MCK) - 243,000 shares, 4.54% of the total portfolio. New Position
  5. Biomarin Pharmaceutical Inc (BMRN) - 302,000 shares, 3.53% of the total portfolio. New Position
New Purchase: Seattle Genetics Inc (SGEN)

Avidity Partners Management LP initiated holding in Seattle Genetics Inc. The purchase prices were between $95.75 and $119.97, with an estimated average price of $110.87. The stock is now traded at around $158.38. The impact to a portfolio due to this purchase was 9.25%. The holding were 580,000 shares as of .

New Purchase: Merck & Co Inc (MRK)

Avidity Partners Management LP initiated holding in Merck & Co Inc. The purchase prices were between $66.4 and $92.04, with an estimated average price of $82.63. The stock is now traded at around $76.29. The impact to a portfolio due to this purchase was 5.23%. The holding were 492,000 shares as of .

New Purchase: McKesson Corp (MCK)

Avidity Partners Management LP initiated holding in McKesson Corp. The purchase prices were between $115.75 and $170.96, with an estimated average price of $146.83. The stock is now traded at around $154.45. The impact to a portfolio due to this purchase was 4.54%. The holding were 243,000 shares as of .

New Purchase: Biomarin Pharmaceutical Inc (BMRN)

Avidity Partners Management LP initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $71.37 and $96.85, with an estimated average price of $86.22. The stock is now traded at around $111.32. The impact to a portfolio due to this purchase was 3.53%. The holding were 302,000 shares as of .

New Purchase: Regeneron Pharmaceuticals Inc (REGN)

Avidity Partners Management LP initiated holding in Regeneron Pharmaceuticals Inc. The purchase prices were between $336.18 and $494.43, with an estimated average price of $411.31. The stock is now traded at around $603.10. The impact to a portfolio due to this purchase was 3.37%. The holding were 50,000 shares as of .

New Purchase: Cardinal Health Inc (CAH)

Avidity Partners Management LP initiated holding in Cardinal Health Inc. The purchase prices were between $41 and $60.42, with an estimated average price of $52.05. The stock is now traded at around $53.66. The impact to a portfolio due to this purchase was 3.35%. The holding were 505,000 shares as of .

Added: AbbVie Inc (ABBV)

Avidity Partners Management LP added to a holding in AbbVie Inc by 407.45%. The purchase prices were between $64.5 and $97.79, with an estimated average price of $85.41. The stock is now traded at around $95.74. The impact to a portfolio due to this purchase was 4.03%. The holding were 477,000 shares as of .

Added: Mirati Therapeutics Inc (MRTX)

Avidity Partners Management LP added to a holding in Mirati Therapeutics Inc by 360.94%. The purchase prices were between $69.78 and $128.86, with an estimated average price of $90.44. The stock is now traded at around $105.63. The impact to a portfolio due to this purchase was 2.45%. The holding were 295,000 shares as of .

Added: Catalent Inc (CTLT)

Avidity Partners Management LP added to a holding in Catalent Inc by 346.74%. The purchase prices were between $36.95 and $62.95, with an estimated average price of $54.82. The stock is now traded at around $71.27. The impact to a portfolio due to this purchase was 2.29%. The holding were 411,000 shares as of .

Added: Momenta Pharmaceuticals Inc (MNTA)

Avidity Partners Management LP added to a holding in Momenta Pharmaceuticals Inc by 290.00%. The purchase prices were between $18.96 and $33.96, with an estimated average price of $27.82. The stock is now traded at around $35.15. The impact to a portfolio due to this purchase was 2.18%. The holding were 780,000 shares as of .

Added: Aurinia Pharmaceuticals Inc (AUPH)

Avidity Partners Management LP added to a holding in Aurinia Pharmaceuticals Inc by 409.48%. The purchase prices were between $11.34 and $21.46, with an estimated average price of $17.73. The stock is now traded at around $16.28. The impact to a portfolio due to this purchase was 1.9%. The holding were 1,182,000 shares as of .

Added: ACADIA Pharmaceuticals Inc (ACAD)

Avidity Partners Management LP added to a holding in ACADIA Pharmaceuticals Inc by 561.11%. The purchase prices were between $31.65 and $46.87, with an estimated average price of $41.34. The stock is now traded at around $47.12. The impact to a portfolio due to this purchase was 1.77%. The holding were 357,000 shares as of .

Sold Out: Baxter International Inc (BAX)

Avidity Partners Management LP sold out a holding in Baxter International Inc. The sale prices were between $71.57 and $93.3, with an estimated average price of $86.41.

Sold Out: HCA Healthcare Inc (HCA)

Avidity Partners Management LP sold out a holding in HCA Healthcare Inc. The sale prices were between $68.13 and $151.04, with an estimated average price of $130.36.

Sold Out: Zimmer Biomet Holdings Inc (ZBH)

Avidity Partners Management LP sold out a holding in Zimmer Biomet Holdings Inc. The sale prices were between $80.63 and $160.4, with an estimated average price of $135.85.

Sold Out: Edwards Lifesciences Corp (EW)

Avidity Partners Management LP sold out a holding in Edwards Lifesciences Corp. The sale prices were between $52.41 and $81, with an estimated average price of $72.39.

Sold Out: Axonics Modulation Technologies Inc (AXNX)

Avidity Partners Management LP sold out a holding in Axonics Modulation Technologies Inc. The sale prices were between $16.44 and $37.73, with an estimated average price of $29.8.

Sold Out: NextCure Inc (NXTC)

Avidity Partners Management LP sold out a holding in NextCure Inc. The sale prices were between $32.32 and $58.37, with an estimated average price of $44.81.



Here is the complete portfolio of Avidity Partners Management LP. Also check out:

1. Avidity Partners Management LP's Undervalued Stocks
2. Avidity Partners Management LP's Top Growth Companies, and
3. Avidity Partners Management LP's High Yield stocks
4. Stocks that Avidity Partners Management LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)